News|Videos|September 22, 2026
FDA Grants Final Approval of Emerging Radiopharmaceutical for GEP-NET Treatment
Author(s)Jeff Hall
Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.
Advertisement
The Food and Drug Administration (FDA) has approved Bravnetsa (lutetium Lu 177 dotatate) for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients.
Approved via the FDA’s abbreviated new drug application (ANDA) pathway, the radiopharmaceutical may be utilized in treating foregut, midgut and hindgut tumors, according to Lantheus, the developer of
Noting the challenges with treating the often slow growing tumors, Lantheus said Bravnetsa provides another treatment option for GEP-NETs that reportedly affect nearly 200,000 patients in the United States.
“As the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to Lutathera approved in the United States, Bravnetsa’s approval marks an important milestone for Lantheus as we continue to expand our radiopharmaceutical portfolio, bringing additional treatment options to people living with GEP-NETs,” said Mary Anne Heino, the executive chairperson and CEO of Lantheus.
Advertisement
Related to this article
Catch up on the top radiology content of the past week.
In a recent interview, Amir Iravani, MD, FRACP, discussed the radiotherapeutic agent 177Lu-edotreotide and new dosimetry data from the COMPETE trial that was recently presented at the ASTRO conference.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Catch up on the most-well viewed radiology content in September 2026.
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Catch up on the most well-viewed video interviews from Diagnostic Imaging in September 2026.
Given the increasing prevalence of Alzheimer’s disease and a staggering number of people with dementia who are undiagnosed, this author discusses five essential keys for radiologists and their colleagues to facilitate earlier detection, precision care treatment and monitoring to help ensure timely care and intervention.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What New Dosimetry Data Reveals About 177Lu-Edotreotide for GEP-NET Treatment
2
Diagnostic Imaging’s Weekly Scan: October 4 — October 10
3
The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 3
4
Key Sessions of Interest for Radiologists at the Upcoming HLTH USA Conference
5